WALTHAM,
Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of
Syndax, will participate in a panel discussion on novel mechanisms
in oncology at the Citi 2024 Global Healthcare Conference on
Thursday, December 5, 2024 at
11:00 a.m. ET.
A live webcast of the panel can be accessed from the Investor
section of the Company's website at www.syndax.com, where a replay
will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include Revuforj® (revumenib),
an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr),
an FDA-approved monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to
reimagining cancer care, Syndax is working to unlock the full
potential of its pipeline and is conducting several clinical trials
across the continuum of treatment. For more information, please
visit www.syndax.com or follow the Company on X (formerly
Twitter) and LinkedIn.
Syndax Contacts
Sharon
Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-citi-2024-global-healthcare-conference-302316980.html
SOURCE Syndax Pharmaceuticals, Inc.